FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family,
discovered in the cytoplasm of almost all types of mammalian cells, plays a significant role in …

The implementation of targeted therapies for acute myeloid leukaemia (AML) has been
challenging because of the complex mutational patterns within and across patients as well …

The therapeutic areas of infectious diseases and oncology have benefited from abundant
scaffold diversity in natural products, able to interact with many specific targets within the cell …

Effective targeted cancer therapeutic development depends upon distinguishing disease-
associated 'driver'mutations, which have causative roles in malignancy pathogenesis, from …

Abstract Between 10% and 40% of newly diagnosed patients with acute myeloid leukemia
(AML) do not achieve complete remission with intensive induction therapy and are therefore …

Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately
30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease …

Covering: 2005 to 2007 Natural product and natural product-derived compounds that are
being evaluated in clinical trials or are in registration (as at 31st December 2007) have been …

FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML).
FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class …

Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …